Yeh C.-C.YI-TING DENGSha D.-Y.Hsiao M.YEN-PING KUO2021-07-052021-07-0520091535-7163https://www.scopus.com/inward/record.uri?eid=2-s2.0-70349481308&doi=10.1158%2f1535-7163.MCT-09-0211&partnerID=40&md5=3513f71eeab59700ed79fe5094a33cf7https://scholars.lib.ntu.edu.tw/handle/123456789/569184Suberoylanilide hydroxamic acid has been shown to selectively induce tumor apoptosis in cell cultures and animal models in several types of cancers and is about as a promising new class of chemotherapeutic agents. In addition, suberoylanilide hydroxamic acid showed synergistic anticancer activity with radiation,cisplatin, and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in some cancers. Here, we report suberoylanilide hydroxamic acid also induced apoptosis in human oral cancer cells. Western blotting showed suberoylanilide hydroxamic acid increased Fas, Fas ligand, DR4, and DR5 protein expression and activated caspase-8 and caspase-9. The apoptosis was almost completely inhibited by caspase-8 inhibitor Z-IETD-FMK and attenuated by caspase-9 inhibitor Z-LEHD-FMK. Human recombinant DR5/Fc chimera protein but not Fas/Fc or DR4/Fc significantly inhibited apoptosis induced by suberoylanilide hydroxamic acid. These results suggest that suberoylanilide hydroxamic acid induces apoptosis mainly through activation of DR5/TRAIL death pathway. Furthermore,s ubtoxic concentrations of suberoylanilide hydroxamic acid sensitize two TRAIL resistant human oral cancer cells, SAS and Ca9-22, to exogenous recombinant TRAIL-induced apoptosis in a p53-independent manner. Combined treatment of suberoylanilide hydroxamic acid and TRAIL may be used as a new promising therapy for oral cancer. Copyright ? 2009 American Association for Cancer Research.[SDGs]SDG3benzyloxycarbonylisoleucylglutamylthreonylaspartyl fluoromethyl ketone; benzyloxycarbonylleucylglutamylhistidylaspartyl fluoromethyl ketone; caspase 8; caspase 9; death receptor 4; death receptor 5; Fas antigen; Fas ligand; protein p53; recombinant protein; tumor necrosis factor related apoptosis inducing ligand; vorinostat; apoptosis; article; cancer cell destruction; cancer combination chemotherapy; cancer inhibition; cancer resistance; carcinoma cell; chemosensitization; concentration response; controlled study; drug potentiation; enzyme activation; human; human cell; mouth carcinoma; priority journal; protein expression; signal transduction; squamous cell carcinoma; upregulation; Western blotting; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Drug Synergism; Humans; Hydroxamic Acids; In Situ Nick-End Labeling; Mouth Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligandjournal article10.1158/1535-7163.MCT-09-0211197379412-s2.0-70349481308